# BioAge Labs

> Clinical-stage biotech targeting metabolic disease and aging biology (public: BIOA).

## Why it is interesting

AI-driven target discovery from longitudinal health records; lead asset azelaprag in obesity trials with Lilly partnership — a16z among crossover health backers pre-IPO.

## Profile

- **Stage:** public
- **Status:** public
- **Industries:** healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series D (Feb 2024): $170M led by Sofinnova; a16z Bio + Health among existing investors (Reuters)
- IPO (Sep 2024) on Nasdaq following obesity-program partnership momentum with Eli Lilly
- Co-investors not in VCT directory: Sofinnova Investments, Longitude Capital, RA Capital, Lilly Ventures
- Source: https://ir.bioagelabs.com/news-releases/news-release-details/bioage-announces-170-million-oversubscribed-series-d-financing

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/khosla-ventures
- https://venturecapitaltracker.com/fund/f-prime-capital
- https://venturecapitaltracker.com/fund/third-rock-ventures

---
Source: https://venturecapitaltracker.com/startup/bioage-labs